A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

[1] Aapro MS(2006)EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2433-2453

[2] Cameron DA(2008)Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin′s lymphoma Br J Cancer 99 253-258

[3] Pettengell R(2005)Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials J Clin Oncol 23 4198-4214

[4] Bohlius J(2004)Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228-237

[5] Crawford J(2005)Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas N Engl J Med 353 988-998

[6] Ellis M(2007)Rational selection of patients for antibacterial prophylaxis after chemotherapy J Clin Oncol 25 4821-4828

[7] Kearney N(2003)Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials J Natl Compr Cancer Netw 1 440-454

[8] Lyman GH(1998)Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis J Clin Oncol 16 1179-1187

[9] Tjan-Heijnen VC(1999)A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy N Engl J Med 341 305-311

[10] Walewski J(2005)Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients Ann Intern Med 142 979-995

[1] Aapro MS(2006)EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2433-2453

[2] Cameron DA(2008)Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin′s lymphoma Br J Cancer 99 253-258

[3] Pettengell R(2005)Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials J Clin Oncol 23 4198-4214

[4] Bohlius J(2004)Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228-237

[5] Crawford J(2005)Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas N Engl J Med 353 988-998

[6] Ellis M(2007)Rational selection of patients for antibacterial prophylaxis after chemotherapy J Clin Oncol 25 4821-4828

[7] Kearney N(2003)Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials J Natl Compr Cancer Netw 1 440-454

[8] Lyman GH(1998)Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis J Clin Oncol 16 1179-1187

[9] Tjan-Heijnen VC(1999)A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy N Engl J Med 341 305-311

[10] Walewski J(2005)Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients Ann Intern Med 142 979-995